Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 5, Pages 407–412
http://dx.doi.org/10.1155/2013/267697
Clinical Study

Asymmetric and Symmetric Dimethylarginine in Adolescents with Hyperuricemia

Department of Pediatrics and Nephrology, Medical University of Bialystok, 17 Waszyngtona Street, 15-274 Bialystok, Poland

Received 10 March 2013; Revised 18 August 2013; Accepted 27 August 2013

Academic Editor: Mariann Harangi

Copyright © 2013 Edyta Tenderenda-Banasiuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. V. Selby, G. D. Friedman, and C. P. Quesenberry Jr., “Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries,” American Journal of Epidemiology, vol. 131, no. 6, pp. 1017–1027, 1990. View at Google Scholar · View at Scopus
  2. R. J. Johnson, D.-H. Kang, D. Feig et al., “Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?” Hypertension, vol. 41, no. 6, pp. 1183–1190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. G. Wannamethee, “Serum uric acid is not an independent risk factor for coronary heart disease,” Current Hypertension Reports, vol. 3, no. 3, pp. 190–196, 2001. View at Google Scholar · View at Scopus
  4. U. M. Khosla, S. Zharikov, J. L. Finch et al., “Hyperuricemia induces endothelial dysfunction,” Kidney International, vol. 67, no. 5, pp. 1739–1742, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. George and A. D. Struthers, “Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress,” Vascular Health and Risk Management, vol. 5, pp. 265–272, 2009. View at Google Scholar · View at Scopus
  6. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,” The Lancet, vol. 339, no. 8793, pp. 572–575, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. P. O. Bonetti, L. O. Lerman, and A. Lerman, “Endothelial dysfunction: a marker of atherosclerotic risk,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 168–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. H. Böger, R. Maas, F. Schulze, and E. Schwedhelm, “Elevated levels of asymmetric dimethylarginine (ADMA) as a marker for cardiovascular disease and mortality,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 10, pp. 1124–1129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Y. Lin, A. Ito, T. Asagami et al., “Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase,” Circulation, vol. 106, no. 8, pp. 987–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. I. Closs, F. Z. Basha, A. Habermeier, and U. Förstermann, “Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B,” Nitric Oxide, vol. 1, no. 1, pp. 65–73, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-M. Hwu and K.-H. Lin, “Uric acid and the development of hypertension,” Medical Science Monitor, vol. 16, no. 10, pp. RA224–RA230, 2010. View at Google Scholar · View at Scopus
  12. Z. Kulaga, M. Litwin, M. Tkaczyk et al., “The height-, weight-, and BMI-for-age of Polish school-aged children and adolescents relative to international and local growth references,” BMC Public Health, vol. 10, article 109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. de Onis, A. Onyango, E. Borghi, A. Siyam, M. Bl?ssner, and C. Lutter, “Worldwide implementation of the WHO child growth standards,” Public Health Nutrition, vol. 15, pp. 1603–1610, 2012. View at Publisher · View at Google Scholar
  14. C. Zoccali, R. Maio, F. Mallamaci, G. Sesti, and F. Perticone, “Uric acid and endothelial dysfunction in essential hypertension,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1466–1471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W.-J. Ho, W.-P. Tsai, K.-H. Yu et al., “Association between endothelial dysfunction and hyperuricaemia,” Rheumatology, vol. 49, no. 10, pp. 1929–1934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Tomiyama, Y. Higashi, B. Takase et al., “Relationships among hyperuricemia, metabolic syndrome, and endothelial function,” American Journal of Hypertension, vol. 24, no. 7, pp. 770–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Zharikov, K. Krotova, H. Hu et al., “Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells,” American Journal of Physiology—Cell Physiology, vol. 295, no. 5, pp. C1183–C1190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D.-H. Kang, S.-K. Park, I.-K. Lee, and R. J. Johnson, “Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells,” Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 3553–3562, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. L. G. Sánchez-Lozada, E. Tapia, R. López-Molina et al., “Effects of acute and chronic L-arginine treatment in experimental hyperuricemia,” American Journal of Physiology—Renal Physiology, vol. 292, no. 4, pp. F1238–F1244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Gonzalez and A. P. Selwyn, “Endothelial function, inflammation, and prognosis in cardiovascular disease,” American Journal of Medicine, vol. 115, supplement 8, pp. 99S–106S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Higashi, K. Noma, M. Yoshizumi, and Y. Kihara, “Endothelial function and oxidative stress in cardiovascular diseases,” Circulation Journal, vol. 73, no. 3, pp. 411–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. H. Böger, “Association of asymmetric dimethylarginine and endothelial dysfunction,” Clinical Chemistry and Laboratory Medicine, vol. 41, pp. 1467–1472, 2003. View at Google Scholar
  23. I. Palomo, A. Contreras, L. M. Alarcón et al., “Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome,” Nitric Oxide, vol. 24, no. 4, pp. 224–228, 2011. View at Google Scholar
  24. C. Korandji, M. Zeller, J. C. Guilland et al., “Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: A model related to metabolic syndrome,” Atherosclerosis, vol. 214, no. 2, pp. 310–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Surdacki, M. Nowicki, J. Sandmann et al., “Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension,” Journal of Cardiovascular Pharmacology, vol. 33, no. 4, pp. 652–658, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. R. H. Böger, S. M. Bode-Böger, A. Szuba et al., “Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia,” Circulation, vol. 98, no. 18, pp. 1842–1847, 1998. View at Google Scholar · View at Scopus
  27. J. Sladowska-Kozlowska, M. Litwin, A. Niemirska et al., “Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy,” Pediatric Nephrology, vol. 27, no. 10, pp. 1943–1951, 2012. View at Google Scholar
  28. I. Kanazawa, S. Yano, Y. Notsu, T. Yamaguchi, T. Nabika, and T. Sugimoto, “Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus,” Clinical Endocrinology, vol. 74, no. 4, pp. 467–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Krzyzanowska, F. Mittermayer, H.-P. Kopp, M. Wolzt, and G. Schernthaner, “Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 12, pp. 6277–6281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Wasilewska, E. Tenderenda, K. Taranta-Janusz, J. Tobolczyk, and J. Stypułkowska, “Markers of systemic inflammation in children with hyperuricemia,” Acta Paediatrica, International Journal of Paediatrics, vol. 101, no. 5, pp. 497–500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Tojo, W. J. Welch, V. Bremer et al., “Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney,” Kidney International, vol. 52, no. 6, pp. 1593–1601, 1997. View at Google Scholar · View at Scopus
  32. E. Schepers, D. V. Barreto, S. Liabeuf et al., “Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2374–2383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Meinitzer, J. T. Kielstein, S. Pilz et al., “Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the ludwigshafen risk and cardiovascular health study,” Clinical Chemistry, vol. 57, no. 1, pp. 112–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Schulze, A. M. Carter, E. Schwedhelm et al., “Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke,” Atherosclerosis, vol. 208, no. 2, pp. 518–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Zoccali, S. M. Bode-Böger, F. Mallamaci et al., “Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study,” The Lancet, vol. 358, no. 9299, pp. 2113–2117, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Fleck, F. Schweitzer, E. Karge, M. Busch, and G. Stein, “Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases,” Clinica Chimica Acta, vol. 336, no. 1-2, pp. 1–12, 2003. View at Publisher · View at Google Scholar · View at Scopus